Next-Generation Antibodies
Fully computational pipelines that provide outstanding antibodies for any target.Reach pre-clinical phases in 3-5 days.
Next-Generation Antibodies
Fully computational pipelines that provide outstanding antibodies for any target.Reach pre-clinical phases in 3-5 days.
The Problem
The Situation
Traditionally, generating antibody candidates against new targets has taken months or even years, delaying therapeutic programs and often resulting in high costs that are only uncovered during preclinical phases or later.
The Solution
Next-Generation Antibodies
We generate in silico humanized antibody sequences for your given target.Enabling you to move from target identification to in vitro validation faster and more efficiently than ever before without compromising quality.
Target Versatility
From viral surface proteins to cancer biomarkers, immunology markers, and membrane proteins—choose your target.
Computational Pipelines
Starting with curated human sequences from quality-controlled databases, our platform recursively improves antibodies through a validated approach. Our in silico maturation process mirrors natural human germinal center evolution, maximizing efficacy while minimizing adverse reaction risks.
Next-Generation Antibodies
Premium shortlist of fully human antibodies that fast-track clinical studies. Our platform delivers superior thermostability, expert-validated sequences, manufacturing readiness, and improved expression yields with minimal off-target binding. Future developments will further reduce cross-reactivity.
Target Versatility
From viral surface proteins to cancer biomarkers, immunology markers, and membrane proteins—choose your target.
Computational Pipelines
Starting with curated human sequences from quality-controlled databases, our platform recursively improves antibodies through a validated approach. Our in silico maturation process mirrors natural human germinal center evolution, maximizing efficacy while minimizing adverse reaction risks.
Next-Generation Antibodies
Premium shortlist of fully human antibodies that fast-track clinical studies. Our platform delivers superior thermostability, expert-validated sequences, manufacturing readiness, and improved expression yields with minimal off-target binding. Future developments will further reduce cross-reactivity.
About Us
The Team
Led by a team of international experts in biology, healthcare, AI and technology.
Next-generation antibodies in under a week
Submit the short form below and our scientists will respond within 24 hours.
We care about your data in our privacy policy.
The Problem
The Situation
Previously, target to pre-clinical study antibodies took months to years, when in reality it is now same-week delivery.
Antibody Candidate Prediction
For any given target, within a week we generate outstanding human antibody candidates, predicted to have suitable characteristics (affinity, kon, kD) as well as good developability characteristics including manufacturing — allowing you to move from target identification to validation faster than ever before.